WAVi

Executive Summary

WAVi is a Boulder-based digital health company commercializing an FDA-cleared EEG system designed to streamline brain assessments in clinical settings. Its integrated hardware-software platform delivers rapid, objective brain data to aid diagnosis and monitoring, making EEG accessible to clinicians without specialized training. By addressing the gap in point-of-care brain health tools, WAVi targets a growing market driven by rising dementia and TBI awareness. The company has established a foothold with regulatory clearance but remains private with limited public financial data. Growth prospects hinge on expanding clinical adoption, securing partnerships with healthcare systems, and pursuing additional indications. Key challenges include competition from traditional EEG providers and demonstrating cost-effectiveness. With an experienced team and a differentiated product, WAVi is positioned for gradual expansion, though near-term visibility is constrained by its pre-revenue profile.

Upcoming Catalysts (preview)

• Q3 2026Publication of pivotal clinical study for concussion assessment70% success
• Q4 2026Strategic partnership with a major hospital network for pilot deployment60% success
• Q1 2027FDA 510(k) clearance for pediatric indication50% success